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A B S T R A C TWe argue that orphan drug policies have been useful in incentivizing
socially desirable R&D and that in their absence it is unlikely that
treatments of any kind would have emerged. Weaknesses in the
current policy framework need to be addressed by refining this
framework rather than altogether replacing or dismissing it as
inefficient. Improvements can be made in data collection, and efforts
are already under way at the European Union level with initiatives
concerning registries. Similarly, the legislative framework can be
refined to define when an orphan treatment is ‘‘sufficiently profitable,’’
at what stage should profits be considered excessive, and, conse-
quently, whether any favorable conditions offered to manufacturers
should be removed. Concerns about availability and accessibility of
orphan drugs, which are valid in many instances, do not imply thatnt matter Copyright & 2012, International Society
r Inc.
.1016/j.jval.2012.08.2202
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ondence to: Panos Kanavos, Department of Social
A 2AE, UK.the current orphan drug policy framework is deficient but that
the means of assessment need to be improved upon for realistic
and affordable prices for payers to become the norm. This implies
better data quality, the possible extension of the criteria for value
assessment to take explicitly into account the peculiarities of rare
diseases, and the availability of appropriate benchmarks around rare
disease cost and quality of life to conduct meaningful value
assessments.
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Outcomes Research (ISPOR). Published by Elsevier Inc.In a recent study by Cote and Keating [1], the authors discussed
the effects of orphan drug policies on availability, accessibility,
and fairness and adopted a qualitative and inductive approach
using grounded theory [2]. In this article, we discuss some of their
article’s salient features and offer our perspective on orphan drug
policies.
In their critique of orphan drug policies, Cote and Keating
raise four issues; these merit further commentary. The first
relates to the argument that orphan drug policies provide an
incentive for manufacturers to concentrate on lucrative areas
such as oncology, as evidenced by the higher proportion of
oncology treatments developed compared with other therapy
areas. While the outcome in terms of drugs produced cannot be
disputed, the likely link between orphan drug policy intent and its
actual outcome should be interpreted with caution, in the absence
of several parameters in the analysis that may influence this
outcome; for example, a key reason why more cancer therapies
may have been discovered and marketed could be that many
potentially treatable rare diseases—about 22% of them—are (rare)
cancers [3], although this figure still needs further clarification
[4]. The higher proportion of rare cancers could also be a result of
an increased incidence of cancer, which is a consequence of an
ageing population [5–7]. It may also be a consequence of govern-
ment funding programs targeting cancer treatments (e.g., New
Drug Funding Programme implemented by Cancer Care Ontarioin Canada) or other regulatory measures implemented to address
gaps in value assessment (e.g., supplementary advice for end-of-
life treatments issued by the National Institute for Health and
Clinical Excellence in England) [5]. Overall, the argument about
the likely lucrative nature of cancer treatments could provide
part of but not all the explanation.
The second issue is the problem of accessibility due to high
prices. While we agree in part with their assessment, the authors
provide no arguments to advance the debate on returns to
innovators and on access. Orphan drug prices are constantly
questioned and contested in the literature, the main issue being
whether or not they deserve ‘‘special status’’ because of the small
number of patients affected and whether rarity can provide the
justification for a higher price. Some argue that all patients
should benefit from the same quality of care based on equity
and on societal preferences [8,9]; others believe that it is a
question of opportunity costs or costs forgone from treating
one patient with a rare condition versus a much larger number
of patients with a ‘‘normal’’ condition with similar characteristics
[10]. Our view is that the above arguments present problems in
their conceptualization because of three conflicting elements:
first, there is complete absence of appropriate benchmarks and
metrics to gauge whether prices are low, high, or too high relative
to expectations; prices are relative to value and a pertinent
question in this context is whether all value parameters havefor Pharmacoeconomics and Outcomes Research (ISPOR).
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Second, it is socially desirable to develop treatments for condi-
tions carrying very high disease severity or having significant
unmet medical need—irrespective of their rarity—and for appro-
priate returns to be awarded to innovators; and third, in the
context of orphan drugs, this desire is supported by a regulatory
framework, which, in principle, should make the cost of drug
discovery and development lower, as also acknowledged by the
authors.
In assessing value and, consequently, rewards to innovators,
our standard tools are not necessarily sufficient to take these
considerations into account; lack of data and incomplete regis-
tries are partly responsible for this. Efforts are currently being
made to address this—at least in part—and create the evidence
base about the cost of a number of rare diseases and the quality
of life of patients with rare disease and their carers through the
Burden of Disease and Quality of Life project [11]; further efforts
are undertaken to leverage as well as coordinate registries;
indeed, there are four complementary European Union initiatives
to improve patient registries for rare diseases: the EPIRARE
project, the PARENT joint action, the EUCERD joint action, and
the International Rare Disease Research Consortium. The overall
aim of these initiatives is to establish common data sets, quality
criteria, and a political framework [12]. The creation of this
evidence base and the above networks and initiatives is long
overdue and could act as a benchmark or proxy benchmark in
value assessments of new orphan treatments.
The third issue identified is the lucrative business opportunities
for manufacturers in developing orphan drugs in general. It is
undeniable that there have been cases in which certain orphan
drugs have had very high returns. Again, to argue whether these
have been excessive or not, appropriate benchmarks are needed.
Such benchmarks would be useful to assess whether high or
excessive returns are a problem specifically for orphan drugs, or
whether this is general to targeted therapies characterized, for
example, as treatments for severe or life-threatening conditions,
curative therapies, or where no other treatment alternatives exist.
The fourth issue relates to the explanatory factors for the
excessive focus on orphan drugs and their profitability for manu-
facturers that have been put forward by the authors, although it is
not clear in which manner they were identified. Among them are
fast-tracking and protocol assistance, excessive stratification of
diseases, old molecules being rediscovered for orphan indications,
and off-label use of orphan drugs. Fast-tracking and protocol
assistance is not unique to rare diseases and orphan drugs,
although these are indeed more likely to be eligible. The former
relates to the overall regulatory framework for pharmaceuticals,
stating the conditions under which patients may benefit from early
access to treatment [13–15]. Protocol assistance was explicitly
implemented to encourage orphan drug development and access,
since given the small number of patients affected, it is more
challenging to generate robust evidence [16]. Our view is that
protocol assistance is necessary across the board to ensure that
all stakeholders concerned (regulators, manufacturers, and
patients) are involved in the generation of appropriate evidence
that, ultimately, benefits society.
The issue of excessive stratification of diseases and multiple
indications of orphan drugs (salami slicing) has been debated
widely in the literature [9,17,18]. It is undeniable that disease
targets have in many instances become narrower and the
scientific ability to address narrow disease targets has over time
become greater. Our view is that we ought to see this as an
achievement rather than as a handicap or a nuisance. Ultimately,
any argument about the stratification of diseases and whether
these are justifiable or not need to be addressed by scientific
evidence; if peer reviewed scientific validation is provided to
justify a new indication, then the policy question is how to assessvalue in this indication. This raises—again—the issue of price
relative to value and the comparison of proposed prices against
objective benchmarks about the cost to sufferers, carers, and
society. Further, evidence shows that prices tend to be set
according to a product’s single indication and do not consider
its total prevalence across the multiple indications[19]. This may
indeed generate excessive returns to manufacturers and may
need to be addressed more aggressively by regulators. In such
cases, for example, Article 8.2 of the European regulation on
orphan drugs may apply, where the 10-year market exclusivity
period could be reduced if the product is shown to be sufficiently
profitable [20].
It is true that old molecules are often rediscovered for a new
indication—in some cases orphan—and that the pricing arrange-
ments for a new use are unsatisfactory. High prices of orphan
drugs have been explained as mainly a consequence of a mono-
polistic position, and consequently on the willingness to pay for
the treatment [9]. We may ask ourselves, however, whether this
price setting that is based on willingness to pay is any different
from what we see in other disease areas? Here the key issue is
that the evidence accepted for orphan drugs tends to be less
robust than for other drugs and the question remains whether
this should be acceptable over the longer term.
Finally, the argument is put forward that the off-label use of
orphan drugs provides another business opportunity. As much as
this statement can be true, we would argue that this is an issue
that is not specific to orphan drugs but to most other therapy
areas and, particularly, cancer (including pediatric cancer) treat-
ments [21].
In conclusion, orphan drug policies have been useful in
incentivizing socially desirable R&D in a sensitive area of public
policy. In the absence of the present framework, it is unlikely that
treatments of any kind would have emerged. Where weaknesses
can be identified, these need to be addressed in the context of the
existing framework rather than altogether replacing it or dis-
missing it as inefficient. For example, improvements can be made
in data collection, and efforts are already under way at the
European Union level with initiatives concerning registries.
Similarly, the legislative framework can be refined to define
when an orphan treatment is ‘‘sufficiently profitable’’ and at what
stage should profits be considered excessive and, consequently,
whether any favorable conditions offered to manufacturers
should be removed. Concerns about availability and accessibility,
which are valid in many instances, do not imply that orphan drug
policy frameworks are deficient but that the means of assess-
ment need to be improved upon for realistic and affordable prices
to become the norm. This implies better data quality, the possible
extension of the criteria for value assessment to take explicitly
into account the peculiarities of rare diseases (e.g., severity,
paucity of evidence), and the availability of appropriate bench-
marks around cost and quality of life of rare diseases to conduct
meaningful value assessments.Acknowledgment
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